Your SlideShare is downloading. ×
0
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Stem cell therapy
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Stem cell therapy

1,897

Published on

Published in: Education, Technology
0 Comments
4 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
1,897
On Slideshare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
241
Comments
0
Likes
4
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. STEM CELLTHERAPY
  • 2. Stem CellStem Cells• Are undifferentiated “master” cell that do not have a specific function Can change to one or several different cell types (differentiate) under proper conditions Can undergo unlimited cell division, self- renewal.
  • 3. DISCARDED STEM CELLSEmbryonicExcess IVF embryos.FetalAborted FetusesAdult stem cellsCord bloodCord (Wharton’s Jelly)PlacentaAmnion, Amniotic fluidEndometrium, Menstrual blood,Milk Teeth and Wisdom teeth
  • 4. Adult stem cell• A subset of cells which maintain and repair the tissues in which they reside.• They are the attractive candidates for cell based therapies as: (i) They do not raise ethical conflicts. (ii) They offer the scope of auto transplantation without the problem of allogenic graft rejection.
  • 5. 08/09/12 Dr. Hariom Yadav
  • 6. Immunological barriers• Rejection- mediated by class 1 MHC and by antigen presenting cells harbouring the class 2 MHC antigen.• Can be overcome by marrow transplantation to induce immunological control.• Somatic Cell Nuclear Transfer.
  • 7. MESENCHYMAL STEM CELLS MESENCHYMAL STEM CELLS ARE MOST PREFERED STEM CELLS FOR CLINICAL APPLICATION
  • 8. No risk of No risk of rejection – used teratoma Pluripotent across HLA formation barrier PreciseNo ethical identificatioissues n Benefits of Ease ofImmune mesenchymal isolation andprivileged stem cell scale upGreater Geneticpotency of stabilityculturedexpanded Lower cost Homogeneousproduct Efficient large of population and scale cell culture high rate of cell expansion process division
  • 9. Application in Diabetes
  • 10. Pancreas and IsletsIslet beta cells Isolated Islets in culture Histology of the pancreasexpressing insulin
  • 11. Possible mechanisms of islet β-cell birth
  • 12. Cell Death mechanisms• Apoptosis (Programmed cell death)• Diabetogenic insults• Cytotoxicity (Drug induced, virus induced,autoimmune)• Glucotoxicity• Lipotoxicity• Cytoprotection of beta cells can prevent diabetes and delay diabetic complications.
  • 13. Beta cell apoptosis
  • 14. Normal mouse Experimental diabetic
  • 15. Characterization of human umbilical cord mesenchymal stem cellsKI67 / Nuclei SMA / Nuclei Nestin Nuclei DesminNuclei Vimentin NucleiMajority of the cells obtained from the cord showed homogenous mesenchymalpopulation (stained positive for CD44, 73, 90 and 117). The cells expressed themesenchymal markers such as nestin, vimentin, desmin and smooth muscleactin. Oct4, an embryonic stem cells marker was also found to be expressed inthese cord derived MSCs.
  • 16. Islet neogenesis from cord MSCs Day 10 DTZ positive ILC Day 0 Day 2 Nucleus/Glucagon/InsulinCord MSCs migrate to form Islet like Clusters (ILCs) upon exposure to Serum FreeMedium (SFM) supplemented with growth factors involved in pancreaticdevelopment.The ILCs are positive for DTZ staining and exhibit immunopositivity for pancreatichormones viz; insulin and glucagon.
  • 17. Placenta derived stem cells
  • 18. Generation of Islet-like Cells Aggregates from DPSCs
  • 19. In vitro charecterizationn of ILSCs
  • 20. Transplanted MSCs & ILCs
  • 21. Indications• New-onset insulin-dependent diabetes mellitus;• Diabetes mellitus complicated by diabetic glomerulosclerosis, chronic renal failure (grade 1 and 2) and anemic syndrome;• Labile course of diabetes mellitus;• Diabetes mellitus associated with infections and immune deficiency;• Presence of resistantance to treatment trophic ulcers of the soft tissues;• Secondary sulfanilamide resistance
  • 22. Diabetic Cardiomyopathy
  • 23. Peripheral Neuropathy
  • 24. Diabetic Nephropathy• Injected MSCs engraft in damaged kidneys, differentiate into renal cells, and regulate the immune response resulting in an efficient treatment of diabetic nephropathy .• Additionally, the small percentage of hMSCs in the transplanted kidneys differentiated into endothelial cells as evidenced by de novo expression of CD31• MSCs are able to reconstitute necrotic segments of diabetic kidneys
  • 25. Wound Healing• Systemic (I.V) and local administration of bone marrow-derived MSCs significantly increased collagen levels followed by increased wound-breaking strength I moderate (TGF-β, KGF) or significant (EGF, PDGF, and VEGF) increase. neovascularization and formation of inflammation infiltrate, containing predominantly mononuclear cells, without tissue necrosis formed sweat or sebaceous gland-like structures of the skin.
  • 26. Diabetic foot• Infusions of stem cells intra-arterially and I.M in each foot possibly avoids the need for amputation.• Stem cell injection supposedly results in 70-80 percent improvement in pus and wounds
  • 27. Limitations of MSCs• Poor engraftment and limited differentiation under in vivo conditions• The frequency of spontaneous differentiation of MSCs in the host tissue is extremely rare• Additional limitation is the potential of MSCs to differentiate into unwanted mesenchymal lineages• Possible malignant transformation and cytogenetic aberrations of MSCs.
  • 28. Conclusion• Because of their immunomodulatory ability, self-renewal, and differentiation capacity, MSCs are expected to become promising therapeutic agents for improvement of diabetes, it’s complications like DCM, nephropathy, DPN, and wounds in diabetic patients.

×